The stock of Phathom Pharmaceuticals Inc (PHAT) has gone down by -11.58% for the week, with a -22.49% drop in the past month and a -63.52% drop in the past quarter. The volatility ratio for the week is 7.23%, and the volatility levels for the past 30 days are 7.02% for PHAT. The simple moving average for the past 20 days is -9.36% for PHAT’s stock, with a -46.27% simple moving average for the past 200 days.
Is It Worth Investing in Phathom Pharmaceuticals Inc (NASDAQ: PHAT) Right Now?
Additionally, the 36-month beta value for PHAT is 0.54. There are mixed opinions on the stock, with 5 analysts rating it as a “buy,” 2 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for PHAT is 34.90M and currently, short sellers hold a 40.70% ratio of that float. The average trading volume of PHAT on January 31, 2025 was 1.28M shares.
PHAT) stock’s latest price update
Phathom Pharmaceuticals Inc (NASDAQ: PHAT)’s stock price has decreased by -3.21 compared to its previous closing price of 6.55. However, the company has seen a -11.58% decrease in its stock price over the last five trading sessions. globenewswire.com reported 2025-01-29 that FLORHAM PARK, N.J., Jan. 29, 2025 (GLOBE NEWSWIRE) — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that members of the management team will participate in a fireside chat at the Guggenheim Securities SMID Cap Biotech Conference on Thursday, February 6, 2025, at 10:00 am ET.
Analysts’ Opinion of PHAT
Many brokerage firms have already submitted their reports for PHAT stocks, with Stifel repeating the rating for PHAT by listing it as a “Buy.” The predicted price for PHAT in the upcoming period, according to Stifel is $24 based on the research report published on May 03, 2024 of the previous year 2024.
Needham, on the other hand, stated in their research note that they expect to see PHAT reach a price target of $26, previously predicting the price at $23. The rating they have provided for PHAT stocks is “Buy” according to the report published on January 05th, 2024.
H.C. Wainwright gave a rating of “Buy” to PHAT, setting the target price at $28 in the report published on August 09th of the previous year.
PHAT Trading at -19.95% from the 50-Day Moving Average
After a stumble in the market that brought PHAT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -67.83% of loss for the given period.
Volatility was left at 7.02%, however, over the last 30 days, the volatility rate increased by 7.23%, as shares sank -20.75% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -30.25% lower at present.
During the last 5 trading sessions, PHAT fell by -11.58%, which changed the moving average for the period of 200-days by -37.48% in comparison to the 20-day moving average, which settled at $6.99. In addition, Phathom Pharmaceuticals Inc saw -21.92% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PHAT starting from Henderson Molly, who sale 6,583 shares at the price of $6.59 back on Jan 21 ’25. After this action, Henderson Molly now owns 93,546 shares of Phathom Pharmaceuticals Inc, valued at $43,371 using the latest closing price.
Nabulsi Azmi, the Chief Operating Officer of Phathom Pharmaceuticals Inc, sale 7,886 shares at $6.59 during a trade that took place back on Jan 21 ’25, which means that Nabulsi Azmi is holding 233,390 shares at $51,957 based on the most recent closing price.
Stock Fundamentals for PHAT
Current profitability levels for the company are sitting at:
- -10.96 for the present operating margin
- 0.85 for the gross margin
The net margin for Phathom Pharmaceuticals Inc stands at -12.92. The total capital return value is set at -0.89.
Based on Phathom Pharmaceuticals Inc (PHAT), the company’s capital structure generated -16.48 points at debt to capital in total, while cash flow to debt ratio is standing at -1.4. The debt to equity ratio resting at -0.94. The interest coverage ratio of the stock is -4.33.
Currently, EBITDA for the company is -159.05 million with net debt to EBITDA at 0.58. When we switch over and look at the enterprise to sales, we see a ratio of 10.48. The receivables turnover for the company is 1.25for trailing twelve months and the total asset turnover is 0.07. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.73.
Conclusion
In conclusion, Phathom Pharmaceuticals Inc (PHAT) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
